Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of two dose levels of LDE225 in advanced basal cell carcinoma
NL-OMON38204Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonidegib in basal cell carcinoma (BCC) (2 arms), sponsored by Novartis. Primary endpoint: Objective response rate. Started Oct 2011; status: active, not recruiting.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON38204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38204.